Finch Therapeutics Group (Finch Therapeutics Group) Price-to-Tangible-Book

: 0.17 (As of Today)

View and export this data going back to 2021. Start your Free Trial

As of today (2024-04-19), Finch Therapeutics Group's share price is $2.36. Finch Therapeutics Group's Tangible Book per Share of Dec. 2023 for the quarter that ended in Dec. 2023 was $14.25. Hence, Finch Therapeutics Group's Price to Tangible Book Ratio of today is 0.17.

The historical rank and industry rank for Finch Therapeutics Group's Price-to-Tangible-Book or its related term are showing as below:

FNCH' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.16 Med: 0.37 Max: 3.13
Current: 0.17

During the past 5 years, Finch Therapeutics Group's highest Price to Tangible Book Ratio was 3.13. The lowest was 0.16. And the median was 0.37.

FNCH's Price-to-Tangible-Book is ranked better than
98.61% of 1223 companies
in the Biotechnology industry
Industry Median: 2.7 vs FNCH: 0.17

A closely related ratio is called PB Ratio. As of today, Finch Therapeutics Group's share price is $2.36. Finch Therapeutics Group's Book Value per Sharefor the quarter that ended in Dec. 2023 was $14.25. Hence, Finch Therapeutics Group's P/B Ratio of today is 0.17.

Finch Therapeutics Group Price-to-Tangible-Book Historical Data

The historical data trend for Finch Therapeutics Group's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Finch Therapeutics Group Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Price-to-Tangible-Book

3.13

0.37

0.25

Finch Therapeutics Group Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Price-to-Tangible-Book													0.37	0.57	0.49	0.32	0.25

Competitive Comparison

For the Biotechnology subindustry, Finch Therapeutics Group's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Finch Therapeutics Group Price-to-Tangible-Book Distribution

For the Biotechnology industry and Healthcare sector, Finch Therapeutics Group's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Finch Therapeutics Group's Price-to-Tangible-Book falls into.

Finch Therapeutics Group Price-to-Tangible-Book Calculation

Finch Therapeutics Group's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book	=	Share Price	/	Tangible Book per Share (Q: Dec. 2023 )
	=	2.36	/	14.252
	=	0.17

It can also be calculated from the numbers for the whole company:

Price to Tangible Book	=	Market Cap	/	Tangible Equity
	=	Market Cap	/	(Total Stockholders Equity	-	Preferred Stock	-	Intangible Assets)

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.

Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.

Finch Therapeutics Group Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Finch Therapeutics Group's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.

Finch Therapeutics Group (Finch Therapeutics Group) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Finch Therapeutics Group Inc (NAS:FNCH) » Definitions » Price-to-Tangible-Book

Comparable Companies

Traded in Other Exchanges

N/A

Address

200 Inner Belt Road, Suite 400, Somerville, MA, USA, 02143

Website

https://www.finchtherapeutics.com

Finch Therapeutics Group Inc is a clinical-stage microbiome therapeutics company. It is leveraging Human-First Discovery platform to develop a novel class of orally administered biological drugs. It is developing novel therapeutics to deliver missing microbes and their clinically relevant biochemical functions to correct dysbiosis and the diseases that emerge from it. The lead product candidate is CP101 which delivers a complete microbiome and is being developed initially for the treatment of patients with recurrent Clostridioides difficile infection.

Executives

Jeffery A Smisek	director	1600 SMITH STREET, HQSEO, HOUSTON TX 77002
Susan E Graf	director	400 TECHNOLOGY SQUARE, 4TH FLOOR, CAMBRIDGE MA 02139
Lance E Thibault	officer: Chief Financial Officer
Matthew P. Blischak	officer: Chief Executive Officer	C/O FINCH THERAPEUTICS GROUP, INC., 200 INNER BELT ROAD, SOMERVILLE MA 02143
Joseph Vittiglio	officer: Chief Business & Legal Officer	C/O BLUEBIRD BIO, INC., 455 GRAND UNION BLVD, SOMERVILLE MA 02145
Marc Blaustein	officer: Chief Operating Officer	C/O FINCH THERAPEUTICS GROUP, INC., 200 INNER BELT ROAD, SUITE 400, SOMERVILLE MA 02143
Domenic J Ferrante	director	BROOKSIDE CAPITAL MANAGEMENT LLC, JOHN HANCOCK TOWER, 200 CLARENDON STREET, BOSTON MA 02116
Samuel A Hamood	director	C/O TRANSUNION, 555 WEST ADAMS STREET, CHICAGO IL 60661
Joanne L. Viney	director	C/O HARPOON THERAPEUTICS, INC., 131 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Nicholas Haft	director	C/O FINCH THERAPEUTICS GROUP, INC., 200 INNER BELT ROAD, SUITE 400, SOMERVILLE MA 02143
Christian H. Lange	director	28 HAVEMEYER PLACE, GREENWICH CT 06830
Crestovo Investor Llc	director, 10 percent owner	28 HAVEMEYER PLACE, GREENWICH CT 06830
Gregory D Perry	officer: Chief Financial Officer	C/O IMMUNOGEN, INC., 830 WINTER ST., WALTHAM MA 02451
Chris Shumway	director, 10 percent owner	28 HAVEMEYER PLACE, GREENWICH CT 06830
Zain Kassam	officer: Chief Medical Officer	C/O FINCH THERAPEUTICS GROUP, INC., 200 INNER BELT ROAD, SUITE 400, SOMERVILLE MA 02143